• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand

    7/29/25 5:00:00 AM ET
    $ATR
    $HLN
    Plastic Products
    Industrials
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $ATR alert in real time by email

    The Freepod® nasal spray pump, globally used with the Otrivin® brand, is now made from 52% bio-based feedstock

    Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally. The use of more sustainable renewable plastic resources is a meaningful measure to help reduce the use of fossil-based materials in healthcare primary packaging.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250729770203/en/

    Aptar Pharma's Freepod® nasal spray pump delivers Haleon's Otrivin® (Image courtesy of Haleon)

    Aptar Pharma's Freepod® nasal spray pump delivers Haleon's Otrivin® (Image courtesy of Haleon)

    Reinforcing circularity in pharmaceutical packaging

    Aptar Pharma's Freepod® spray pump used with Haleon's Otrivin® Nasal Spray is made of 52% ISCC Plus certified bio-based feedstock. The bottle is produced using a mass balance approach equivalent to 100% bio-based content. Together, the pump and bottle components result in an overall circular material content of 60% for the full nasal spray device.

    ISCC PLUS certified manufacturing and supply chain

    Aptar Pharma is committed to helping its customers meet their sustainability goals, such as reducing the use of fossil-based materials in packaging. The Freepod® nasal spray components are made from bio-based resins derived from renewable feedstocks like bio-waste and residual oils, using an ISCC PLUS-certified mass balance approach. The Aptar Pharma manufacturing site in Mezzovico, Switzerland, is ISCC PLUS certified, ensuring full traceability of materials throughout the manufacturing process and supply chain. ISCC Plus certification also covers all external suppliers - including injection molding providers, service partners, and warehouses - guaranteeing a fully (ISCC) certified supply chain for the Freepod® components.

    Partnership for a more sustainable approach

    The joint sustainability approach between Haleon (formerly GSK Consumer Healthcare) and Aptar Pharma is built on a long-term partnership spanning over 30 years. This collaboration has led to significant achievements, including the Otrivin® Freepod® winning the World Packaging Award in 2019 for its innovative and sustainable design.

    The use of bio-based or renewable feedstocks for the Otrivin® products with Freepod® technology supports Haleon's goal to reduce virgin petroleum-based plastic use by 10% by 2025** and by a third by 2030, compared to 2022 levels. Aptar Pharma's Freepod® for Otrivin®, available globally, demonstrates Aptar's commitment to sustainability and innovation. Looking ahead, this collaboration is anticipated to extend to Otrivin Nasal Mist, Haleon's latest microdroplet technology, which is being rolled out globally since 2023.

    "At Aptar, sustainability is not just a responsibility - it's a strategic advantage," commented Gael Touya, President of Aptar Pharma. "The launch of Freepod® Futurity™ reflects our commitment to developing solutions that respond to consumers' increasing demand for more sustainable healthcare delivery technologies. As a trusted partner to Haleon, we are proud to help drive the success of the Otrivin® brand while enabling a shift away from fossil-based materials in primary packaging. Supporting our partners in reaching their environmental goals reinforces our vision of supporting the healthcare industry, from Formulation to patient."

    With a strong commitment to sustainability, Aptar Pharma continuously strives to reduce its environmental impact and support its partners in achieving their sustainability goals.

    *ISCC Plus certified bio-based feedstock, mass balance approach.

    **The end point for the goal delivery period is the end of the 2025 calendar year.

    About Aptar Pharma

    Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

    About Haleon

    Haleon (LSE/NYSE:HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250729770203/en/

    Media Contact:

    Ciara Jackson

    Aptar Pharma

    +49 151 1951 6502

    [email protected]

    Get the next $ATR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATR
    $HLN

    CompanyDatePrice TargetRatingAnalyst
    Haleon plc
    $HLN
    5/27/2025$13.40Neutral → Outperform
    BNP Paribas Exane
    Haleon plc
    $HLN
    5/9/2025$11.25Equal-Weight → Overweight
    Morgan Stanley
    Haleon plc
    $HLN
    3/5/2025Buy → Hold
    HSBC Securities
    Haleon plc
    $HLN
    1/10/2025Overweight → Equal-Weight
    Morgan Stanley
    Haleon plc
    $HLN
    1/8/2025Outperform → Mkt Perform
    Bernstein
    AptarGroup Inc.
    $ATR
    1/7/2025$200.00Outperform
    Raymond James
    AptarGroup Inc.
    $ATR
    1/6/2025$173.00Buy → Neutral
    BofA Securities
    AptarGroup Inc.
    $ATR
    10/14/2024$155.00 → $215.00Hold → Buy
    Jefferies
    More analyst ratings

    $ATR
    $HLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aptar Reports Second Quarter 2025 Results

    AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following second quarter results for the period ended June 30, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731446602/en/Aptar Reports Second Quarter 2025 Results Second Quarter 2025 Highlights (compared to the prior year quarter) Reported sales increased 6% and core sales increased 3% Reported net income increased 24% to $112 million and adjusted EBITDA increased 13% from the prior year to $218 million Rep

    7/31/25 5:00:00 PM ET
    $ATR
    Plastic Products
    Industrials

    Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand

    The Freepod® nasal spray pump, globally used with the Otrivin® brand, is now made from 52% bio-based feedstock Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally. The use of more sustainable renewable plastic resources is a meaningful measure to help reduce the use of fossil-based materials in healthcare primary packaging. This press release features multimedia. View the full release here:

    7/29/25 5:00:00 AM ET
    $ATR
    $HLN
    Plastic Products
    Industrials
    Package Goods/Cosmetics
    Consumer Discretionary

    New Study Using Aptar's Nasal Drug Delivery System Validates Insulin Nasal Spray to Deliver Alzheimer's Drug Directly to the Brain

    Research by Wake Forest University School of Medicine provides a crucial method for future Alzheimer's disease treatment trials and reveals key differences in how the drug is absorbed in people with early cognitive decline AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its nasal drug delivery system was used in a recently published brain imaging study from Wake Forest University School of Medicine. According to the university's press release, the "groundbreaking" study confirms a vital step toward new Alzheimer's treatments: intranasal insulin, delivered via nasal spray, safely and effectively

    7/23/25 8:29:00 AM ET
    $ATR
    Plastic Products
    Industrials

    $ATR
    $HLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Segment President Prieur Marc sold $305,606 worth of shares (2,000 units at $152.80), decreasing direct ownership by 11% to 15,745 units (SEC Form 4)

    4 - APTARGROUP, INC. (0000896622) (Issuer)

    6/16/25 10:52:48 AM ET
    $ATR
    Plastic Products
    Industrials

    EVP and Chief Legal Officer Chainey Kimberly sold $255,318 worth of shares (1,671 units at $152.79), decreasing direct ownership by 13% to 11,088 units (SEC Form 4)

    4 - APTARGROUP, INC. (0000896622) (Issuer)

    6/10/25 5:57:51 PM ET
    $ATR
    Plastic Products
    Industrials

    Segment President Touya Gael sold $503,654 worth of shares (3,300 units at $152.62), decreasing direct ownership by 9% to 33,963 units (SEC Form 4)

    4 - APTARGROUP, INC. (0000896622) (Issuer)

    6/9/25 12:40:43 PM ET
    $ATR
    Plastic Products
    Industrials

    $ATR
    $HLN
    SEC Filings

    View All

    SEC Form 6-K filed by Haleon plc

    6-K - Haleon plc (0001900304) (Filer)

    8/19/25 6:01:53 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 6-K filed by Haleon plc

    6-K - Haleon plc (0001900304) (Filer)

    8/18/25 6:09:08 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 6-K filed by Haleon plc

    6-K - Haleon plc (0001900304) (Filer)

    8/15/25 7:52:38 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    $ATR
    $HLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Haleon plc upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Haleon plc from Neutral to Outperform and set a new price target of $13.40

    5/27/25 9:05:49 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Haleon plc upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Haleon plc from Equal-Weight to Overweight and set a new price target of $11.25

    5/9/25 8:39:10 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Haleon plc downgraded by HSBC Securities

    HSBC Securities downgraded Haleon plc from Buy to Hold

    3/5/25 7:28:35 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    $ATR
    $HLN
    Leadership Updates

    Live Leadership Updates

    View All

    HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

    LONDON, June 24, 2025 /PRNewswire/ -- Haleon (LSE: HLN) (NYSE:HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025.  This appointment follows Franck Riot deciding to leave Haleon after six years in the business.  Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care.  Brian McNamara, Haleon's Chief Executive Officer commented: "I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experi

    6/24/25 8:00:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Haleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation

    WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- Haleon, a world-leading consumer health company, is pleased to announce the appointment of Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024.  In this role, Joe will lead the organization's customer strategy, driving growth and transformation in the US market. Joe brings extensive leadership experience to the role, having spent over 20 years in the FMCG sector and serving in the military. Most recently Joe led Unilever's Walmart business, overseeing the company's largest US customer. In his

    12/2/24 7:53:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Aptar CFO, Robert (Bob) Kuhn, Has Decided to Step Down After 37 Years with the Company

    Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,

    7/25/24 5:20:00 PM ET
    $ATR
    Plastic Products
    Industrials

    $ATR
    $HLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Haleon plc

    SC 13G - Haleon plc (0001900304) (Subject)

    11/13/24 1:20:28 PM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Haleon plc

    SC 13D/A - Haleon plc (0001900304) (Subject)

    10/3/24 6:59:16 PM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Haleon plc

    SC 13D/A - Haleon plc (0001900304) (Subject)

    10/1/24 7:38:46 PM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    $ATR
    $HLN
    Financials

    Live finance-specific insights

    View All

    Aptar Reports Second Quarter 2025 Results

    AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following second quarter results for the period ended June 30, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731446602/en/Aptar Reports Second Quarter 2025 Results Second Quarter 2025 Highlights (compared to the prior year quarter) Reported sales increased 6% and core sales increased 3% Reported net income increased 24% to $112 million and adjusted EBITDA increased 13% from the prior year to $218 million Rep

    7/31/25 5:00:00 PM ET
    $ATR
    Plastic Products
    Industrials

    Aptar Declares Quarterly Dividend

    AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is August 14, 2025 to stockholders of record as of July 24, 2025. As previously announced, Aptar will hold a conference call on Friday, August 1, 2025 at 8:00 a.m. Central Time to discuss the Company's second quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. A

    7/10/25 5:00:00 PM ET
    $ATR
    Plastic Products
    Industrials

    Aptar Reports First Quarter 2025 Results

    AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill

    5/1/25 5:03:00 PM ET
    $ATR
    Plastic Products
    Industrials